FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

TATEMENT	OF CHA	NGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

1. Name and Address of Reporting Person

S

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

DAVIS JOHN C. JR			Magenta Therapeutics, Inc. [MGTA]										(0		all applic Directo Officer	-		10% Ov			
	GENTA T	First) HERAPEUTICS SY SQUARE				3. Date of Earliest Transaction (Month/Day/Year) 12/09/2019										X	below) Chief Medica			below)	
(Street) CAMBR (City)	IDGE 1	MA State)	02139 (Zip)		4. 1	If Ame	endme	nt, Date (of Origi	nal Fi	iled	(Month/Da	ay/Yea	ar)		Indiv ne) X	Form fi	iled by One	e Repo	g (Check Ap orting Perso n One Repo	n
1. Title of Security (Instr. 3) 2. Transa Date				Execution Date, if any		3. Tra	3. 4. Se Transaction Dispo Code (Instr. 5)			ties A	cquire	eficia d (A) or r. 3, 4 a		5. Amour Securitie Beneficia Owned F	ınt of es ially	Form: Direct		7. Nature of Indirect Beneficial Ownership			
					(Monail Buy, Tear)		Co	de	v	Amount (A) or (D)		Price		Reported Transaction(s (Instr. 3 and 4		(7 (,	(Instr. 4)			
Common Stock		12/09	9/2019			N	1		4,614	4	A	\$9.	49	12,918			D				
Common	Stock			12/09	9/201	19			S	(1)		4,614	4	D	\$1	.5	8,3	304		D	
Common Stock		12/10	0/2019				N	1		17,055		A	\$9.	49	25,	,359		D			
Common Stock 12/			12/10)/2019			S	[1)		17,055 D S		\$1	5 (2)	8,304			D				
			Table II -									sed of, onverti					wned				
Derivative Conversion			3A. Deeme Execution if if any (Month/Day	d 4. Date, T	Tansaction Code (Instr.		5. Number 6.		6. Dat	Date Exercisal xpiration Date Month/Day/Year		able and	7. Ti of So Und Deri	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		t 8. D S (I	erivative ecurity estr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)
				С	ode	v	(A)	(D)	Date Exerc	sable		xpiration ate	Title		or Numbe of Shares						
Stock Option (Right to	\$9.49	12/09/2019			M			4,614	(:	3)	0	4/25/2028		nmon ock	4,614		\$0.00	254,09	9	D	

Explanation of Responses:

\$9,49

- 1. This trade is pursuant to an active 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$15.00 to \$15.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

(3)

17,055

3.25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

Remarks:

Buy) Stock Option

(Right to

Buy)

/s/ Zoran Zdraveski, Attorneyin-Fact for John C. Davis, Jr.

17,055

\$0.00

Common

Stock

04/25/2028

12/10/2019

237,044

D

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/10/2019

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

M

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.